ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Brain organoid start-up System1 Biosciences raises $25 million for neuropsychiatric drug discovery

by Ryan Cross
September 22, 2018 | APPEARED IN VOLUME 96, ISSUE 38

 

System1 Biosciences has raised $25 million in series A financing for its autism, epilepsy, and schizophrenia drug discovery programs. The San Francisco-based start-up will tackle the tough-to-treat conditions by testing drugs on cerebral organoids, which are miniature brainlike organs grown in a lab. System1 is growing its organoids with stem cells from patients with a brain disease. The firm hopes that organoids will provide a more realistic preclinical model than the cells and animals often used in neuropsychiatric drug discovery.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment